Displaying 1 - 20 of 125
In September 2019, the operators of a deceptive negative option scheme agreed to a court-ordered preliminary injunction temporarily barring them from a wide range of conduct. The preliminary injunction stops the defendants from misleading consumers about supposedly “free trial” offers, enrolling them in unwanted continuity plans, billing them without their authorization, and making it nearly impossible for them to cancel or get their money back. In June 2022, the Commission announced it was returning $5.4 million to defrauded consumers.
Statement of Commissioner Rebecca Kelly Slaughter Regarding the Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products
Statement of Commissioner Christine S. Wilson Regarding the FTC Policy Statement on Rebates and Fees in Exchange for Excluding Lower Cost Drug Products
Statement of Commissioner Alvaro M. Bedoya Regarding the Commission's Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products
Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding 6(b) Study of Pharmacy Benefit Managers
FTC Outlines Aggressive Approach to Policing Against Pandemic Predators in Testimony Before Senate Commerce Subcommittee
FTC Comment to Food and Drug Administration Supports Agency’s Proposed Rule on Establishing Over-the-Counter Hearing Aids
With Omicron Variant on the Rise, FTC Orders More Marketers to Stop Falsely Claiming Their Products Can Effectively Prevent or Treat COVID-19
FTC Issues Refunds Totaling More Than $1.8 Million to Consumers Defrauded by Lifewatch, Inc.’s Deceptive Medical Alert Telemarketing Scheme
FTC Sends Refunds to Consumers Who Bought Deceptively Marketed Supplements to Treat Pain and Age-related Health Conditions
In April 2020, the marketers of three supplements called Neurocet, Regenify, and Resetigen-D settled FTC charges that they deceptively promoted their products to older Americans using false claims that their products could stop pain and treat age-related ailments. The proposed order bars the defendants—five related companies and their principals from making any claims about the health benefits of their products unless they are true and supported by scientific evidence. In October 2021, the FTC announced it was returning $1.1 million to consumer who bought the defendants’ products.
FTC Sends Cease and Desist Demands to 10 Companies Suspected of Making Diabetes Treatment Claims without the Required Scientific Evidence
FTC Approves Final Administrative Consent Order against Kushly Industries LLC and its Owner for Making Unsupported Health Claims for CBD Products
FTC Approves Final Administrative Consent Orders against Companies that Deceptively Marketed Fish Oil Supplements with False Claims They Were Clinically Proven to Treat Liver Disease
Federal Trade Commission, FDA Warn Five Companies That May Be Illegally Selling Dietary Supplements Claiming to Treat Infertility
In April 2021, the FTC charged St. Louis-based chiropractor Eric Anthony Nepute and his company Quickwork LLC with violating the COVID-19 Consumer Protection Act and the Federal Trade Commission Act, by deceptively marketing products containing vitamin D and zinc as scientifically proven to treat or prevent COVID-19. This is the first such case in which the agency has sought civil penalties.
The FTC Directed 30 More Marketers to Stop Making Unsupported Claims That Their Products and Therapies Can Effectively Prevent or Treat COVID-19
Displaying 1 - 20 of 125